

People are the building blocks and strength of EBOS.

Contents

| Financial Highlights | 1 |
|---------------------------------------------|-----|
| Shareholder Calendar | 1 |
| Directors' Report | 2 |
| Consolidated Income Statement | 4 |
| Consolidated Statement of Changes in Equity | 5 |
| Consolidated Balance Sheet | 6 |
| Consolidated Cash Flow Statement | 7 |
| Notes to the Interim Financial Statements | 8 |
| Directory | IBC |

Financial Highlights

| | Six Months 31 Dec 08 \$'000 | Six Months 31 Dec 07 \$'000 | Year Ended 30 Jun 08 \$'000 |
|--------------------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Revenue | 691,568 | 465,690 | 1,092,020 |
| EBITDA | 18,104 | 15,228 | 33,634 |
| Profit before income tax expense | 12,065 | 10,419 | 22,543 |
| Profit attributable to members of the parent entity | 8,483 | 7,064 | 16,663 |
| Shareholders' interest | 150,630 | 135,836 | 147,304 |
| Earnings per share | 17.8c | 16.7c | 37.6c |
| Interest cover | 3.9 | 4.0 | 3.7 |
| Net interest bearing debt to net interest bearing debt plus equity | 32.1% | 41.8% | 32.0% |

Shareholder Calendar

| Interim dividend payable | April 2009 |
|-----------------------------|-------------------|
| Release of full year result | Late August 2009 |
| Final dividend payable | Late October 2009 |
| Annual General Meeting | 22 October 2009 |

EBOS Group Limited Directors' Report

The diversity of earning streams established by EBOS Group Ltd during the last few years has provided a strong first half profit for the six months to 31 December 2008.

EBITDA was up 19% to \$18.1 million and net profit after tax was up 20% to \$8.5 million on the corresponding six month result last year. Considering the wider regional slowdown and general uncertainty as to the length of the recession the directors are pleased with this positive momentum.

In any equity market that is struggling to find good news, it is important to stress that this result supports our strategy to create a resilient business with multiple business units capable of withstanding adverse economic cycles.

Earnings per share improved to 17.8 cents, compared with 16.7 cents in the prior corresponding period. Results are unaudited.

All of EBOS businesses in the Healthcare portfolio performed up to expectation and ahead of last year despite the prevailing macroeconomic environment. Our Australian healthcare business was once again our strongest performer.

Of significant importance, given the global liquidity problems, is that EBOS has secured bank facilities for the next three years. EBOS debt to debt plus equity ratio has reduced to 32.1% as at 31 December 2008 against 41.8% in December 2007. This sound position means EBOS is well placed for further expansion.

In the first half, our scientific businesses suffered from their market sector being challenged with capital equipment sales.

We anticipated a cyclical industry downturn in equipment sales when we made the acquisition of the largely consumable based Crown Scientific. Our restructuring of this business to allow for future profitable growth is almost completed.

Outlook

Directors and management will continue to drive operational efficiencies, manage costs, reduce working capital and focus on creating the best structure for all of our businesses, in what is widely regarded as a volatile and challenging business environment.

In this environment, the board expect a number of investment opportunities to arise and will evaluate these to continue with the EBOS growth story.

Bonus share issue distribution

Shareholder support for our bonus share plan, as an alternative to a dividend payout, has historically been high whilst for the Company it preserves cash for expansion.

For our first half result Directors have declared a bonus share distribution of 10.5 cents per share (9.5 cents the previous half year). As before shareholders can elect to redeem these bonus shares, or a portion of them, for cash. The record date for the bonus share distribution is 20 March 2009, and the issue date will be 21 April 2009.

Rick Christie Chairman

6 a to

Mark Waller Chief Executive and Managing Director

y straue

EBOS Group Limited Consolidated Income Statement

For the Six Months ended 31 December 2008 (unaudited)

| | Notes | Six Months 31 Dec 08 \$'000 | Six Months 31 Dec 07 \$'000 | Year Ended 30 Jun 08 \$'000 |
|-------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------|-----------------------------------|-----------------------------------|
| Revenue | 2 | 691,568 | 465,690 | 1,092,020 |
| Profit before depreciation, amortisation, finance costs and income tax expense Depreciation Amortisation of finite life intangibles | 2 2 | 18,104 (1,620) (322) | 15,228 (1,183) (147) | 33,634 (2,620) (137) |
| Profit before finance costs and tax Finance costs | 2 | 16,162 (4,097) | 13,898 (3,479) | 30,877 (8,334) |
| Profit before income tax expense Income tax expense | 2 | 12,065 (3,582) | 10,419 (3,355) | 22,543 (5,880) |
| Profit for the period | | 8,483 | 7,064 | 16,663 |
| Earnings per share Basic (cents per share) Diluted (cents per share) | | 17.8 17.8 | 16.7 16.7 | 37.6 37.6 |

Calculated on a weighted average basis of the numbers of shares on issue.

EBOS Group Limited Consolidated Statement Of Changes In Equity For the Six Months ended 31 December 2008 (unaudited)

| No | tes | Six Months 31 Dec 08 \$'000 | Six Months 31 Dec 07 \$'000 | Year Ended 30 Jun 08 \$'000 |
|--------------------------------------------------------------------|-----|-----------------------------------|-----------------------------------|-----------------------------------|
| Equity at start of period | | 147,304 | 92,195 | 92,195 |
| Profit for the period attributable to members of the parent entity | | 8,483 | 7,064 | 16,663 |
| Movement in foreign currency translation reserve | | (1,517) | 177 | 2,529 |
| Cash flow hedges (loss) taken to equity | | (2,136) | - | (137) |
| Total recognised income and expenses | | 4,830 | 7,241 | 19,055 |
| Dividends paid to company shareholders Shares issued | 4 | (1,504) | (6,075) 42,475 | (6,548) 42,602 |
| Equity at end of period | | 150,630 | 135,836 | 147,304 |

EBOS Group Limited **Consolidated Balance Sheet**As at 31 December 2008 (unaudited)

| | | six months 31 Dec 08 \$'000 | Six months 31 Dec 07 \$'000 | Year ended 30 Jun 08 \$'000 |
|-------------------------------------------|---|-----------------------------------|-----------------------------------|-----------------------------------|
| Current assets | | | | |
| Cash and cash equivalents | | 12,712 | 2,498 | 16,136 |
| Trade and other receivables | | 162,620 | 140,386 | 150,426 |
| Prepayments | | 923 | 3,683 | 2,789 |
| Inventories | | 140,713 | 122,339 | 126,704 |
| Current tax refundable | | 2,712 | 1,582 | 3,428 |
| Other financial assets - derivatives | | 267 | 12 | 130 |
| Finance leases | | 109 | 97 | 108 |
| Total current assets | | 320,056 | 270,597 | 299,721 |
| Non-current assets | | | | |
| Property, plant and equipment | | 19,490 | 18,321 | 22,103 |
| Capital work in progress | | 434 | 3,428 | 916 |
| Finance leases | | 86 | 143 | 115 |
| Prepayments | | 1,016 | 1,336 | 1,176 |
| Deferred tax assets | | 4,552 | 2,012 | 3,992 |
| Goodwill | | 133,331 | 125,753 | 133,062 |
| Indefinite life intangibles | | 23,676 | 23,590 | 23,756 |
| Finite life intangibles | | 1,030 | 1,353 | 1,353 |
| Total non-current assets | | 183,615 | 175,936 | 186,473 |
| Total assets | | 503,671 | 446,533 | 486,194 |
| Current liabilities | | | | |
| Bank overdraft | | 513 | 3,351 | 277 |
| Trade and other payables | | 246,049 | 198,412 | 233,039 |
| Finance leases | | 347 | 363 | 225 |
| Bank loans | | 2,500 | 73,150 | 82,971 |
| Current tax payable | | 2,273 | 1,234 | 1,886 |
| Employee benefits | | 5,027 | 4,750 | 4,851 |
| Other financial liabilities – derivatives | | 3,253 | 110 | 387 |
| Total current liabilities | | 259,962 | 281,370 | 323,636 |
| Non-current liabilities | | | | |
| Bank loans | | 80,121 | 22,261 | 1,250 |
| Trade and other payables | | 5,283 | 4,242 | 5,318 |
| Deferred tax liabilities | | 7,119 | 1,955 | 7,796 |
| Finance leases | | 556 | 869 | 890 |
| Total non-current liabilities | | 93,079 | 29,327 | 15,254 |
| Total liabilities | | 353,041 | 310,697 | 338,890 |
| Net assets | | 150,630 | 135,836 | 147,304 |
| Equity | | | | |
| Share capital | 3 | 105,752 | 105,625 | 105,752 |
| Foreign currency translation reserve | | 527 | (308) | 2,044 |
| Retained earnings | | 46,624 | 30,519 | 39,645 |
| Cash flow hedge reserve | | (2,273) | - | (137 |
| Total equity | | 150,630 | 135,836 | 147,304 |
| | | | | |

EBOS Group Limited Consolidated Cash Flow Statement

For the Six Months ended 31 December 2008 (unaudited)

| Note | | ix months 31 Dec 08 \$'000 | Six months 31 Dec 07 \$'000 | Year ended 30 Jun 08 \$'000 |
|------------------------------------------------------------------------------|---|----------------------------------|-----------------------------------|-----------------------------------|
| Cash flows from operating activities | | | | |
| Receipts from customers | | 678,519 | 404,330 | 1,086,298 |
| Interest received | | 40 | 48 | 234 |
| Payments to suppliers and employees | | (673,462) | (402,122) | (1,041,501) |
| Taxes paid | | (2,829) | (4,296) | (8,151) |
| Interest paid | | (4,097) | (3,479) | (8,334) |
| Net cash (outflow)/inflow from operating activities | 6 | (1,829) | (5,519) | 28,546 |
| Cash flows from investing activities Sale of property, plant & equipment | | 2,721 | 40 | 295 |
| Purchase of property, plant & equipment | | (747) | (1,077) | (6,315) |
| Payments for capital work in progress | | (434) | (2,419) | (150) |
| Businesses acquired | 5 | (1,452) | (84,797) | (86,968) |
| Net cash inflow/(outflow) from investing activities | | 88 | (88,253) | (93,138) |
| Cash flows from financing activities | | | | |
| Proceeds from issue of shares | 3 | - | 28,225 | 28,351 |
| Proceeds from borrowings | | 800 | 107,161 | 59,793 |
| Repayment of borrowings | | (1,250) | (37,566) | (2,500) |
| Dividends paid to equity holders of parent | | (1,504) | (6,075) | (6,548) |
| Net cash (outflow)/inflow from financing activities | | (1,954) | 91,745 | 79,096 |
| Net (decrease)/increase in cash held Effect of exchange rate fluctuations | | (3,695) | (2,027) | 14,504 |
| on cash held | | 35 | 37 | 218 |
| Net cash and cash equivalents at beginning of period | | 15,859 | 1,137 | 1,137 |
| Net cash and cash equivalents at end of period | | 12,199 | (853) | 15,859 |
| Cash and cash equivalents Bank overdrafts | | 12,712 (513) | 2,498 (3,351) | 16,136 (277) |
| | | 12,199 | (853) | 15,859 |
| | | 12,199 | (003) | 10,009 |

EBOS Group Limited

Notes to the Interim Financial Statements

For the Six Months ended 31 December 2008

1. FINANCIAL STATEMENTS

The unaudited interim financial statements have been prepared in accordance with Generally Accepted Accounting Practice in New Zealand ("NZ GAAP"). They comply with New Zealand Equivalent to International Accounting Standard 34 (NZ IAS 34) "Interim Financial Reporting" and other applicable reporting standards appropriate for profit oriented entities.

These financial statements should be read in conjunction with the financial statements and related notes included in the Company's Annual Report for the year ended 30 June 2008.

1.1 Change in accounting estimate

During the six months to 31 December 2007 the group under stated sales revenue and cost of sales by \$63,269,000 respectively. Reassessment of the group's interpretation of NZ IAS 18 'Revenue' prior to 30 June 2008 concluded the group is acting as principal in these transactions.

Previously the group had determined it was acting as agent and the revenue was reported net, as commission. Revenue from the sale of goods and cost of sales for the six months to December 2007 have been re-stated having no effect on reported profit, earnings per share or equity.

EBOS Group Limited

Notes to the Interim Financial Statements (continued)

For the Six Months ended 31 December 2008

2. PROFIT FROM OPERATIONS

| | | Six months 31 Dec 08 \$'000 | Six months 31 Dec 07 \$'000 | Year ended 30 Jun 08 \$'000 |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| (a) | Revenue | | | |
| | Revenue consisted of the following items: | | | |
| | Revenue from the sale of goods | 686,105 | 462,418 | 1,083,068 |
| | Revenue from the rendering of services | 3,871 | 2,066 | 6,101 |
| | Management fees | 1,369 | 1,158 | 2,232 |
| | Interest revenue | 40 | 48 | 234 |
| | Other revenue | 183 | - | 385 |
| _ | | 691,568 | 465,690 | 1,092,020 |
| (b) | Profit before income tax expense Profit before income tax has been arrived at after crediting/(charging) the following gains and losses from operations: | | | |
| | Gain on sale of property, plant and equipme Change in fair value of derivative financial | ent 294 | - | (63) |
| | instruments classified at fair value through profit or loss | 273 | (15) | 75 |
| | Profit before income tax has been arrived a (charging) the following expenses by nature | | | |
| | Cost of sales | (615,109) | (408,955) | (962,491) |
| | Write-down of inventory | - | = | (878) |
| | Finance costs: | | | |
| | Bank interest | (3,893) | (3,479) | (7,667) |
| | Other interest expense | (204) | - | (667) |
| | Total finance costs | (4,097) | (3,479) | (8,334) |
| | Net be all and also death of state | | | (40) |
| | Net bad and doubtful debts | - (4.000) | (4.400) | (40) |
| | Depreciation of property, plant & equipment | | (1,183) | (2,620) |
| | Amortisation of finite life intangibles | (322) | (147) | (137) |
| | Operating lease expenses | (3,712) | (1,844) | (6,176) |
| | Donations | (22) | - | (50) |
| | Employee benefit expense | (29,390) | (20,122) | (52,548) |
| _ | Other expenses | (25,798) | (19,526) | (36,215) |
| _ | Total expenses | (680,070) | (455,256) | (1,069,489) |
| | Profit before income tax expense | 12,065 | 10,419 | 22,543 |

EBOS Group Limited Notes to the Interim Financial Statements (continued)

For the Six Months ended 31 December 2008

3. SHARE CAPITAL

On 10 October 2008 the Company issued 1,114,978 bonus shares under a Profit Distribution Plan bringing the number of shares on issue at 31 December 2008 to 48,136,819 (2007 46,133,513).

4. DIVIDENDS

| | Six months 31 Dec 08 \$'000 | | 31 Dec 08 31 Dec 07 | | 7 30 Jun 08 | |
|----------------------------|-----------------------------------|-----------------|-----------------------|-----------------|-----------------------|-----------------|
| | Cents per share | Total \$'000 | Cents per share | Total \$'000 | Cents per share | Total \$'000 |
| Recognised amounts | | | | | | |
| Fully paid ordinary shares | | | | | | |
| · Final – prior year | 13.5 | 1,504 | 13.0 | 6,075 | 13.0 | 5,998 |
| · Interim - current year | =. | - | - | - | 9.5 | 550 |
| | 13.5 | 1,504 | 13.0 | 6,075 | 22.5 | 6,548 |
| Unrecognised amounts | | | | | | |
| Final dividend | - | - | - | - | 13.5 | 1,504 |
| Interim dividend | 10.5 | 1,200 | | | | |
| | 10.5 | 1,200 | - | - | 13.5 | 1,504 |

5. ACQUISITION OF BUSINESSES

| Name of Business Acquired | d Principal activities | Date of acquisition | Cost of acquisition \$'000 |
|-------------------------------------------------------|---------------------------|---------------------|----------------------------|
| 2009: 100% of business assets of MedBio Limited | Scientific supplies | 1 July, 2008 | 1,452 |
| | | | 1,452 |

Description of Acquisition Activity

| 2009 | Me | Fair value on | | |
|-------------------------------|----------------------|---------------|-----|--|
| | Book value \$'000 | | | |
| Current assets | | | | |
| Trade and other receivables | 233 | - | 233 | |
| Prepayments | 7 | - | 7 | |
| Inventories | 99 | - | 99 | |
| Non-current assets | | | | |
| Property, plant and equipment | 82 | - | 82 | |

EBOS Group Limited Notes to the Interim Financial Statements (continued)

For the Six Months ended 31 December 2008

5. ACQUISITION OF BUSINESSES (Continued)

| Current liabilities Trade and other payables | (100) | - | (100) |
|-----------------------------------------------------|-------|---|-------|
| Net assets acquired | 321 | - | 321 |
| Goodwill on acquisition | 1,131 | - | 1,131 |
| Consideration | 1,452 | - | 1,452 |

The contribution to net surplus for the half year attributable to the purchase of MedBio Limited was \$77,000.

6. NOTES TO THE CASH FLOW STATEMENT

| | x months 31 Dec 08 \$'000 | Six months 31 Dec 07 \$'000 | Year ended 30 Jun 08 \$'000 |
|-----------------------------------------------------------------------------------|---------------------------------|-----------------------------------|-----------------------------------|
| Reconciliation of profit for the period with cash flows from operating activities | | | |
| Profit for the period | 8,483 | 7,064 | 16,663 |
| Add/(less) non-cash items: Depreciation | 1.620 | 1.183 | 2.620 |
| (Gain)/loss on sale of property, | , | , | ,- |
| plant & equipment | (294) | _ | 60 |
| Amortisation of finite life intangibles | 322 | 147 | 137 |
| (Gain)/loss on derivative financial instruments | (273) | 15 | (7: |
| Deferred tax | (376) | (9) | (9 |
| Provision for doubtful debts | (76) | (53) | (3 |
| | 923 | 1,283 | 2,61 |
| Movements in working capital: | | | |
| Trade and other receivables | (12,118) | (99,103) | (109,15 |
| Finance lease receivables | 28 | 18 | 3 |
| Prepayments | 2,026 | (2,497) | (1,44 |
| Inventories | (14,009) | (77,128) | (81,49 |
| Current tax refundable/payable | 1,103 | (806) | (2,00 |
| Trade and other payables | 12,975 | 172,975 | 208,67 |
| Employee benefits | 176 | 2,445 | 2,54 |
| Foreign currency effect on translation of | | | |
| opening working capital balances | (1,655) | 192 | 2,61 |
| | (11,474) | (3,904) | 19,78 |
| Movements in items treated as investing activities | 239 | (9,962) | (10,51 |
| J | | (=,==) | (10,01 |
| Net cash (outflow)/inflow from operating activities | (1,829) | (5,519) | 28,54 |

Notes to the Interim Financial Statements (continued)

For the Six Months ended 31 December 2008

7. SEGMENT INFORMATION

| Ir | ıformation | on bu | usiness | segments | (primary | reporting | format) |
|----|------------|-------|---------|----------|----------|-----------|---------|
| | | | | | | | |

| | Six months 31 Dec 08 \$'000 | Six months 31 Dec 07 \$'000 | Year ended 30 Jun 08 \$'000 |
|-------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Revenue | | | |
| Healthcare | 683,541 | 454,974 | 1,075,945 |
| Scientific | 34,247 | 25,034 | 61,719 |
| Inter-segment | (26,220) | (14,318) | (45,644) |
| | 691,568 | 465,690 | 1,092,020 |
| Profit before finance costs and tax | | | |
| Healthcare | 15,734 | 11,354 | 26,482 |
| Scientific | 428 | 2,544 | 4,395 |
| | 16,162 | 13,898 | 30,877 |
| Profit for the period | | | |
| Healthcare | 8,206 | 5,523 | 13,488 |
| Scientific | 277 | 1,541 | 3,175 |
| | 8,483 | 7,064 | 16,663 |
| Segment assets | | | |
| Healthcare | 458,607 | 406,642 | 442,525 |
| Scientific | 45,064 | 39,891 | 43,669 |
| | 503,671 | 446,533 | 486,194 |
| Segment liabilities | | | |
| Healthcare | 345,294 | 304,545 | 328,732 |
| Scientific | 7,747 | 6,152 | 10,158 |
| | 353,041 | 310,697 | 338,890 |
| | | | |

Information on geographical segments (secondary reporting format)

| information on geographical segme | ormation on geographical segments (secondary reporting format) | | | |
|-------------------------------------|----------------------------------------------------------------|-----------------------------------|-----------------------------------|--|
| | Six months 31 Dec 08 \$'000 | Six months 31 Dec 07 \$'000 | Year ended 30 Jun 08 \$'000 | |
| Revenue | | | | |
| New Zealand | 633,529 | 417,701 | 986,001 | |
| Australia | 84,259 | 62,307 | 151,663 | |
| Inter-segment | (26,220) | (14,318) | (45,644) | |
| | 691,568 | 465,690 | 1,092,020 | |
| Profit before finance costs and tax | | | | |
| New Zealand | 11,035 | 8,375 | 18,702 | |
| Australia | 5,127 | 5,523 | 12,175 | |
| | 16,162 | 13,898 | 30,877 | |
| Profit for the period | | | | |
| New Zealand | 5,457 | 3,804 | 9,073 | |
| Australia | 3,026 | 3,260 | 7,590 | |
| | 8,483 | 7,064 | 16,663 | |
| Segment assets | | | | |
| New Zealand | 420,161 | 380,359 | 411,491 | |
| Australia | 83,510 | 66,174 | 74,703 | |
| | 503,671 | 446,533 | 486,194 | |
| | | | | |

EBOS Group Limited

Directory

Corporate Office

108 Wrights Road PO Box 411 CHRISTCHURCH Telephone (03) 338-0999 Fax (03) 339-5111 E-mail: ebos@ebos.co.nz Internet: www.ebos.co.nz

Other Locations

Auckland Office 243-249 Bush Road PO Box 302-161 Albany, Auckland NEW ZEALAND

Wellington Office 498 Hutt Road Lower Hutt NEW ZEALAND

Subsidiaries

PRNZ Limited 54 Carbine Road Mt Wellington Auckland NEW ZEALAND

Health Support Limited & Health Support Properties Limited 56 Carrington Road, Pt Chevalier Auckland NEW ZEALAND

Global Science & Technology Limited 241 Bush Road, Albany Auckland NEW ZEALAND

Quantum Scientific Pty Limited 31 Archimedes Place Murarrie, Qld AUSTRALIA

EBOS Group Pty Limited Unit 2, 109 Vanessa Street Kingsgrove, NSW 2208 AUSTRALIA

EBOS Health & Science Pty Limited Unit 2, 109 Vanessa Street Kingsgrove, NSW 2208 AUSTRALIA

EBOS Health & Science (PNG) Limited GB House, Kunai Street Hohola, Waigani NCD PAPUA NEW GUINEA

Vital Medical Supplies (Australia) Pty Limited Unit 29-31, 276-278 Newline Road Dural, NSW 2158 AUSTRALIA

Directors

R.G.M. Christie Chairman

M.B. Waller

Chief Executive and Managing Director

P.F. Kraus Deputy Chairman E.M. Coutts

P. Merton

S.C. Ottrey

B.J. Wallace

M. Stewart

Appointed 8 September 2008

Executives

M.B. Waller Chief Executive

M. Broome

General Manager - Healthcare Logistics

D.Brown

Director Scientific Australia and New Zealand

A.J. Cooper

General Manager – Business Development

D.C. Doherty Chief Financial Officer

K.R. Hyland

General Manager – Sales & Marketing Healthcare

D. Lewis

General Manager – ProPharma

G. Managh

General Manager – Health Support Ltd

A. Norris

General Manager – EBOS Group Pty Ltd

Auditor Deloitte

Bankers

ANZ National Bank Limited

Solicitor

Chapman Tripp

Share Register

Computershare Investor Services Ltd Private Bag 92119 Auckland NEW ZEALAND Telephone: (09) 488-8777

Shareholder Enquiries

Shareholders with enquiries about share transactions, change of address or dividend payments should contact the Share Registrar – Computershare Investor Services Ltd.

